openPR Logo
Press release

Glomerulonephritis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AstraZeneca, Novartis, Alnylam, Apellis, Otsuka, Omeros Corporation, ChemoCentryx, Visterra, MorphoSys

12-13-2023 06:26 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Glomerulonephritis Pipeline Analysis (2023) Covering

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, several major pharma and biotech companies are working on various pipeline therapies in the Glomerulonephritis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Glomerulonephritis Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Glomerulonephritis Therapeutics Market.

The report provides a detailed description of the Glomerulonephritis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Glomerulonephritis Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/glomerulonephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Glomerulonephritis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Glomerulonephritis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glomerulonephritis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Glomerulonephritis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Glomerulonephritis treatment market.

Learn More about the Clinical and Commercial Development Activities in the Glomerulonephritis Therapeutics Domain @
https://www.delveinsight.com/report-store/glomerulonephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Glomerulonephritis Therapeutics Analysis
Though there are no FDA-approved drugs for the treatment of Glomerulonephritis, but many different therapies have been studied for the cure of its separate clinical features. The treatment for glomerulonephritis depends on what is causing it. Certain medicines called angiotensin-converting enzyme (ACE) inhibitors such as captopril, lisinopril, perindopril, and angiotensin receptor blockers (ARBs) such as losartan, irbesartan, valsartan can help control blood pressure.

Glomerulonephritis Companies in the Therapeutics Market Include:
• AstraZeneca
• Novartis Pharmaceuticals
• Alnylam Pharmaceuticals
• Apellis Pharmaceuticals
• Otsuka
• Omeros Corporation
• ChemoCentryx
• Visterra
• MorphoSys
• Chinook Therapeutics
And Many Others

Emerging and Marketed Glomerulonephritis Therapies Covered in the Report Include:
• AZD2373: AstraZeneca
• LNPO23: Novartis Pharmaceuticals
• Cemdisiran: Alnylam Pharmaceuticals
• APL-2 : Apellis Pharmaceuticals
• VIS649: Visterra
• Avacopan : ChemoCentryx
• OMS721: Omeros Corporation
And Many More

Request for Sample PDF to Understand More About the Glomerulonephritis Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/glomerulonephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Glomerulonephritis Current Treatment Patterns
4. Glomerulonephritis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Glomerulonephritis Late-Stage Products (Phase-III)
7. Glomerulonephritis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Glomerulonephritis Discontinued Products
13. Glomerulonephritis Product Profiles
14. Glomerulonephritis Companies
15. Glomerulonephritis Drugs
16. Dormant and Discontinued Products
17. Glomerulonephritis Unmet Needs
18. Glomerulonephritis Future Perspectives
19. Glomerulonephritis Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/glomerulonephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Glomerulonephritis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AstraZeneca, Novartis, Alnylam, Apellis, Otsuka, Omeros Corporation, ChemoCentryx, Visterra, MorphoSys here

News-ID: 3326672 • Views:

More Releases from DelveInsight Business Research LLP

Interstitial Lung Disease Pipeline Analysis, 2024: Clinical Trials, FDA, EMA, and PMDA Approvals, Emerging Therapies, and Growth Prospects
Interstitial Lung Disease Pipeline Analysis, 2024: Clinical Trials, FDA, EMA, an …
DelveInsight's, "Interstitial Lung Diseases Pipeline Insight 2024" report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Interstitial Lung Disease pipeline landscape. It covers the Interstitial Lung Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Interstitial Lung Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Glioma Pipeline Analysis, 2024: Clinical Trials, FDA, EMA, and PMDA Approvals, Emerging Therapies, and Growth Prospects
Glioma Pipeline Analysis, 2024: Clinical Trials, FDA, EMA, and PMDA Approvals, E …
DelveInsight's, "Glioma Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Glioma pipeline landscape. It covers the Glioma Pipeline Drug profiles, including clinical and nonclinical stage products. It also covers the Glioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Glioma Pipeline Report • DelveInsight's Glioma
Glioblastoma Pipeline Analysis, 2024: Clinical Trials, FDA, EMA, and PMDA Approvals, Emerging Therapies, and Growth Prospects
Glioblastoma Pipeline Analysis, 2024: Clinical Trials, FDA, EMA, and PMDA Approv …
DelveInsight's, "Glioblastoma Pipeline Insight 2024" report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in the Glioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including Glioblastoma clinical trials and nonclinical stage products. It also covers the Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Glioblastoma Pipeline
Gastric Cancer Pipeline Analysis, 2024: Clinical Trials, FDA, EMA, and PMDA Approvals, Emerging Therapies, and Growth Prospects
Gastric Cancer Pipeline Analysis, 2024: Clinical Trials, FDA, EMA, and PMDA Appr …
DelveInsight's, "Gastric Cancer Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including Gastric Cancer clinical trials and nonclinical stage products. It also covers the Gastric Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Gastric

All 5 Releases


More Releases for Glomerulonephritis

Glomerulonephritis Treatment MarketGrowth, Trends and Value Chain 2018-2028
Glomerulonephritis Treatment Market: Introduction Glomerulonephritis, also known as Bright's disease, is a progressive kidney disease that damages the glomeruli—the filtering units of the kidney that create urine as a waste. There are two types of glomerulonephritis, namely acute glomerulonephritis and chronic glomerulonephritis. The acute glomerulonephritis disease develops suddenly and can be caused by infections, such as strep throat. Acute glomerulonephritis disease can also be caused by infection in the throat or
Glomerulonephritis Treatment Market Set for Rapid Growth And Trend, by 2028
Glomerulonephritis Treatment Market: Introduction Glomerulonephritis, also known as Bright's disease, is a progressive kidney disease that damages the glomeruli—the filtering units of the kidney that create urine as a waste. There are two types of glomerulonephritis, namely acute glomerulonephritis and chronic glomerulonephritis. The acute glomerulonephritis disease develops suddenly and can be caused by infections, such as strep throat. Acute glomerulonephritis disease can also be caused by infection in the throat or
Glomerulonephritis Treatment Market Status by Players, Types, Applications and F …
"The Latest Research Report 2018-2025 Glomerulonephritis Treatment Report on Global and United States Market, Status and Forecast, by Players, Types and Applications provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" This report studies the Glomerulonephritis Treatment market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in
Glomerulonephritis Pharmaceutical and Healthcare Pipeline Review H1
Summary Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV, hepatitis B virus, and hepatitis C virus. Factors that increase chances of getting glomerulonephritis include family
Glomerulonephritis Market Pipeline Review, H2 2017
"The Report Glomerulonephritis - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis - Pipeline Review, H2 2017, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape. Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the
Glomerulonephritis Market: Industry Size, Share, Growth, Forecasts
Latest industry research report on: Glomerulonephritis Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis Pipeline Review, H1 2017, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape. Complete Report Details @ https://www.marketresearchreports.biz/reports/1068016/glomerulonephritis-pipeline-review-h1-2017-market-research-reports Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized